![Mark Rubinstein](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 314 424 $ al 31/08/2026
Mark L.
Rubinstein is Chief Medical Officer at Achieve Life Sciences, Inc. starting in 2025.
Formerly, Dr. Rubinstein was Head-Medical Affairs at Blip Products, Inc. Education includes a doctorate from Yale University.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 28/01/2026 | 39.600 ( 0,04 % ) | 314 424 $ | 31/08/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| ACHIEVE LIFE SCIENCES, INC. | Director Técnico/Científico/I+D | 01/10/2024 |
| Empresas | Cargo | Fin |
|---|---|---|
Blip Products, Inc.
 Blip Products, Inc. Pharmaceuticals: MajorHealth Technology Produces and sells nicotine replacement therapy products through online | Director Técnico/Científico/I+D | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 3 |
|---|---|
Yale University
 Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Achieve Life Sciences, Inc.
 Achieve Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes cytisinicline for smoking cessation and nicotine addiction | Health Technology |
Blip Products, Inc.
Blip Products, Inc. Pharmaceuticals: MajorHealth Technology Produces and sells nicotine replacement therapy products through online | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
